stat6-in-4

IL-4 inhibitor is an inhibitor of IL-4.1It binds to IL-4 with a Kdvalue of 1.8 μM and inhibits IL-4 activity in a cell-based reporter assay (EC50= 1.81 μM). It is selective for IL-4 over IL-13 (EC50= 18.2 μM). IL-4 inhibitor inhibits IL-4-induced STAT6 phosphorylation in THP-1 monocytes (EC50= 3.1 μM), indicating inhibition of the IL-4-JAK1-STAT6 signaling pathway.

YM-341619 (AS1617612) is a potent, orally active STAT6 inhibitor (IC50: 0.70 nM) that inhibits IL-4-induced Th2 differentiation in mouse splenic T cells with an IC50 value of 0.28 nM, without affecting Th1 cell differentiation. YM-341619 holds potential for research into allergic diseases, such as allergic asthma.

Rademikibart (CBP-201) is a human monoclonal antibody selective for IL-4Rα, exhibiting strong affinity with a KD of 20.7 pM for human IL-4Rα epitopes, without cross-reactivity to IL-4Rα from other species. It effectively inhibits IL-4 and IL-13-induced STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMCs, showing promise for investigating moderate-to-severe Th2 inflammatory diseases [1].

7,4'-Dihydroxyflavone (4',7-Dihydroxyflavone) can induce transcription of nodulation (nod) genes in Rhizobium meliloti. It has inhibitory activities against COX-2.